Evidenced-based Product Efficacy

Discover the Foundation of Bonvadis^® in Robust Scientific Research

Bonvadis^®, developed based on ON101, is supported by a multicenter randomized controlled trial and distinctive mechanisms of action, with results published in leading international peer-reviewed journals. Ongoing global real-world evidence further validates its effectiveness and showcases its superior therapeutic benefits.

Join the revolution in wound care today!

MOA – Macrophage Modulation

To accelerate wound healing, ON101 suppresses pro-inflammatory M1 and promotes polarization towards pro-remodeling M2.

Published In: JID Innovations (2022)

MOA – Inhibition of Inflammation

ON101 constituent PA-F4 targets multiple steps of the NLRP3 inflammasome activation pathway, to exert its anti-inflammatory effect.

Published In: Frontiers in Pharmacology (2019)

Multicenter RCT (N=236)

Topical application of ON101 demonstrated a statistically significant healing rate compared with standard care (60.7% vs 35.1%, P = 0.0001) among diabetic foot ulcer (DFU) patients and more.

Published In: JAMA Network Open (2021)

Real-World Evidence – US

ON101 promotes complete closure of hard-to-heal Wagner grade 2 ulcers in US patients, aligning with RCT results.

Poster Publication At: SAWC Spring 2024

Real-World Evidence – Taiwan

ON101 enables effective wound healing for Taiwanese patients with multiple co-morbidities and difficult-to-heal wounds.

Poster Publication At: SAWC Spring 2024

Case Report – Diabetic Patients with Uremia

ON101 demonstrated excellent healing efficacy among DFU patients undergoing dialysis, comparable to previous RCT results.

Published In: Case Reports in Clinical Medicine (2024)

Case Report – Chronic Burn Wound

ON101 delivered favorable outcomes in healing a chronic burn wound within 3 weeks.

Published In: The Journal of Taiwan Society of Plastic Surgery (2024)

Mechanism of Action

ON101 promotes wound healing by rebalancing the expression of pro-inflammatory M1 and pro-healing/pro-remodeling M2 macrophages and their associated cytokines, thereby attenuating chronic inflammation and facilitating the transition to the proliferation phase for tissue regeneration and repair.

Prescription information

DESCRIPTION

Bonvadis^® Topical Cream is a mint-colored, non-sterile, water-based, semi-viscous formulation. It contains methyl paraben and propyl paraben to preserve the product both before opening and between uses.

INDICATIONS

For Prescription Use:  
Under the direction of a healthcare professional, the Rx product is indicated for the management of partial-thickness wounds, closed post-surgical wounds, and 1st-degree and superficial 2nd-degree burns.

Package Insert Download

FAQ

Q1.

Can patients use the product once per day?

A1.

The recommended application frequency is twice per day, however, this frequency is subject to the physician’s professional opinion, i.e. once daily. There are real-world patients who are prescribed to use the product once per day.

Q2.

Are there any contraindications with other therapies?

A2.

ON101 is generally compatible with other therapies such as antibiotics, HBOT, NPWT, skin grafts, etc., though it is advised to avoid the simultaneous use of other topical agents.

Q3.

Can we combine Bonvadis^® with foam dressing?

A3.

Yes. Note that this is subject to the physician’s professional opinion on the outer dressing, i.e. clean gauze, foam dressings, hydrocolloid dressings, and hydrofiber dressings.

Q4.

Why can regulating macrophages promote and accelerate healing? What’s the difference between this mechanism and others (i.e. NPWT, HBOT)?

A4.

M1 and M2 macrophage populations are essential for the complete healing of wounds but both subtypes are dysregulated in chronic wounds. Rather than providing oxygen or absorbing tissue fluids, ON101 reshapes and rebalances chronic wounds’ microenvironment to enable accelerated, better wound healing.
Oxygenation therapy is mainly used for non-ischemic ulcer conditions. NPWT is not recommended for the healing of non-surgical diabetic wounds. Both of these therapies have their limitations. However, ON101, as a macrophage regulator, is not restricted by these conditions. Our randomized controlled trial does not set limitations to ulcer etiology, whether neuropathic, ischemic or neuro-ischemic, ensuring broader applicability and efficacy across different types of ulcers. (Huang et al., 2021)

Q5.

When should I start using the product?

A5.

Once etiological factors (i.e. perfusion, infection) is corrected, Bonvadis® can be applied after sharp debridement.

Q6.

How long is the course of treatment? How many tubes do I need to use?

A6.

~1 tube heals smaller or less complex ulcers in 2-4 weeks. 2 to 3 tubes can heal hard-to-heal ulcers in 8 to 12 weeks.

Q7.

Can we use Bonvadis^® in poorly controlled diabetes patients?

A7.

Yes. Evidence from our RCT and the real world show that even when a patient’s HbA1c level is over 9%, the closure of the ulcer is not affected.

Q8.

Can we use Bonvadis^® in osteomyelitis patients?

A8.

Bonvadis^® can be applied after osteomyelitis tissue or bone is surgically removed.

Evidenced-based Product Efficacy

Mechanism of Action

Prescription information

FAQ

Introduction

Data Collection

Use of Data

Data Sharing

Data Security

Your Rights

Policy Updates

Miscellaneous

Contact Us